Navigation Links
Isis Pharmaceuticals (Nasdaq: ISIS) Letter to Shareholders
Date:11/23/2009

CARLSBAD, Calif., Nov. 23 /PRNewswire-FirstCall/ --

Dear Isis Supporters and Shareholders,

I would like to start by thanking you for your continuing support of Isis. We believe we are at one of the most successful moments in our history. We are truly at the end of the beginning of creating a unique company with a novel drug discovery platform, which we believe addresses many of the issues haunting the pharmaceutical industry.

Our progress is predicated largely upon the success of our flagship drug, mipomersen. Mipomersen continues to perform well and progress toward commercialization. Isis, our investigators and members of the medical community are very encouraged by the results that were presented at the AHA last week. To get a sense of their support of the drug, I would encourage you to listen to the replay of the mipomersen investigator panel presentation that was conducted during AHA last week. I think you will hear not only their enthusiasm for the drug but their hope that mipomersen will provide a new treatment alternative for their patients at very high risk of cardiovascular disease.

We are disappointed with the reaction on Wall Street to what we believe is very positive news. We believe mipomersen will continue to provide results that speak for themselves. Each success brings us closer to getting mipomersen to the market and making the drug available to patients in need.

Our antisense technology provides a direct route from genes to drugs with the opportunity to dramatically improve the productivity of the pharmaceutical industry. With 19 drugs in development, we have one of the largest and most diverse pipelines in our industry. We know that sick people depend on us. We continue to strive for excellence as we create drugs for the future. We also recognize that behind our successes is the support we receive from you. I would like to personally thank you for that.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer
2. Jiangbo Pharmaceuticals to Present at Brean Murray, Carret 2009 China Growth Conference
3. Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results
4. Onyx Pharmaceuticals Reports Third Quarter 2009 Financial Results; Nexavar Global Net Sales Top $229 Million, 27% Increase Over Third Quarter 2008
5. Cumberland Pharmaceuticals to Present at Lazard Healthcare Conference in New York on November 17, 2009
6. Vanda Pharmaceuticals Reports Third Quarter 2009 Results
7. Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
8. VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference
9. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
10. Amira Pharmaceuticals to Present at the BIO Investor Forum in San Francisco
11. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... Javon Bea Mercy Health System CEO ... capable by the State of Illinois, enabling potential stroke ... Hospital. , The hospital was required to submit data ... stroke according to national standards of care for stroke ... bypass hospitals not designated as an Emergent Stroke Ready ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 The World ... and learning materials to potential EMTs and firefighters, recently ... Bitcoins as a way to raise charitable donations for ... in Medellin, Columbia, will be held on March 29, ... run will begin at 3:30 p.m. , To ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Wireless ... management services, and one of the founders ... support for Bell Mobility within their CLEAN Platform™ ... services. Wireless Analytics’ newly developed Bell Mobility ... for the Canadian wireless carrier’s business customers. , ...
(Date:2/27/2015)... 27, 2015 Those who ... often misunderstood, misdiagnosed and therefore aren’t receiving ... lives. Jacksonville-based addiction treatment center Lakeview ... highly acclaimed Lakeview Professional Lecture Series to ... understanding this complicated condition. , ...
(Date:2/27/2015)... 2015 Altec Products, Inc., announced today ... chosen as their doc-link for Dynamics Partner of the ... complimentary solutions for their customers in all different industries ... Altec and BPW have worked side-by-side to successfully help ... GP. , “We are so impressed by the success ...
Breaking Medicine News(10 mins):Health News:Mercy Harvard Hospital Recognized as Leader in Stroke Care - Javon Bea 2Health News:Bitcoin Run Is The World Scout League Commission’s Newest Project for Charity 2Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 2Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 3Health News:Lakeview Health to Host Important Workshop Tackling the Rising Issue of ‘Cutters’ on March 27 2Health News:Altec Announces 2014 doc-link for Dynamics Partner of the Year Award Recipient 2Health News:Altec Announces 2014 doc-link for Dynamics Partner of the Year Award Recipient 3
... asthma symptoms fall after just a week away, study finds, ... week away from urban air pollution, children with mild persistent ... , A study in the March issue of ... of school-age children left the city for a rural area, ...
... Pennsylvania Game Commission wildlife biologists continue to monitor bat ... confirmed infected or dying from White Nose Syndrome (WNS) ... mines near Carbondale, Lackawanna County; an abandoned mine near ... Aitkin Cave and Seawra Cave in Mifflin County."We continue ...
... Align Technology, Inc. (Nasdaq: ALGN ... Teen(TM) for non-adult, comprehensive orthodontic treatment. Invisalign Teen ... effectiveness of the Invisalign(R) system, with new features ... teeth, and root-movement control - issues that are ...
... who wear those hats and T-shirts are likely to drink ... 2 (HealthDay News) -- All those T-shirts, hats and other ... more than just a fashion statement. , , Teens who ... become binge drinkers, a new study contends. , The Dartmouth ...
... Stem cells can thrive in segments of ... researchers at the Stanford University School of Medicine. ... nooks and crannies, the so-called "bioscaffold" can then ... , The new technique neatly sidesteps a fundamental ...
... ARBOR, Mich., March 2 Researchers from the ... a gene that is overexpressed in 90 percent of ... the gene, Ataxia Telangiectasia Group D Complementing gene, called ... cancer cells than in cells from a normal pancreas. ...
Cached Medicine News:Health News:City Kids Find the Breathin' Is Easier Elsewhere 2Health News:City Kids Find the Breathin' Is Easier Elsewhere 3Health News:WNS Identified at Six Sites in Pennsylvania 2Health News:Align Technology Announces International Availability of Invisalign Teen(TM) 2Health News:Align Technology Announces International Availability of Invisalign Teen(TM) 3Health News:Alcohol-Branded Apparel Linked to Adolescent Drinking 2Health News:Alcohol-Branded Apparel Linked to Adolescent Drinking 3Health News:Alcohol-Branded Apparel Linked to Adolescent Drinking 4Health News:Technique may help stem cells generate solid organs, Stanford study shows 2Health News:Technique may help stem cells generate solid organs, Stanford study shows 3Health News:U-M Researchers ID Gene Involved in Pancreatic Cancer 2
(Date:2/27/2015)... Laboratories Corp. (OTC:DWTPD), a Delaware ... Laboratories, Inc., a Toronto corporation ... investors of units consisting of its common stock and ... Shares of the Company,s common stock will continue to ... "DWTPD" until FINRA,s approval of the ticker "BNKL." ...
(Date:2/26/2015)... RnRMarketResearch.com adds Corneal Ulcers ... to its store. This report p provides an ... The report "Corneal Ulcers - Pipeline Review, H2 2014" ... Corneal Ulcers. Corneal Ulcers are primarily result of ... infections & fungal infections. The symptoms of the ...
(Date:2/26/2015)... Feb. 26, 2015  IRIDEX Corporation (NASDAQ: IRIX ... and full year 2014 financial results after the market closes ... the release, the Company will host a conference call with ... Thursday, March 5, 2015 to discuss the ... Interested parties may access the live conference call via telephone ...
Breaking Medicine Technology:Bionik Laboratories Raises $6.2 Million 2Bionik Laboratories Raises $6.2 Million 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 4Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 5IRIDEX Announces Fourth Quarter and Full Year 2014 Conference Call and Release Date 2
... DIEGO, Sept. 8, 2011 Marshall Edwards, Inc. (Nasdaq: ... the clinical development of novel therapeutics targeting cancer metabolism, ... trial of the Company,s lead drug candidate ME-143 in ... conducted in collaboration with the Sarah Cannon Research Institute ...
... Sept. 8, 2011 ChromaDex® Corp. (OTCBB: CDXC) ... has granted ChromaDex® the exclusive rights to a ... university for the method of inducing UDP-glucuronosyltransferase (UGT) ... a compound found in blueberries and demonstrated to ...
Cached Medicine Technology:Marshall Edwards Announces Initiation of Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143 2Marshall Edwards Announces Initiation of Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143 3ChromaDex®'s Novel Ingredient pTeroPure® to be Studied as Potential Treatment for Fighting Skin Cancers 2ChromaDex®'s Novel Ingredient pTeroPure® to be Studied as Potential Treatment for Fighting Skin Cancers 3
The AV Plus DX pacing lead is designed for use with the St. Jude Medical Affinity VDR pulse generator. This single-lead pacing system provides reliable pacing therapy with the added benefits of AV sy...
Steroid eluting pacemaker leads...
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
The Medtronic Model 6495 bipolar coaxial temporary pacing lead is designed to provide the advantages of bipolar technology based on the sensing and pacing capabilities of the Medtronic Model 6500 uni...
Medicine Products: